How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.

Détails

ID Serval
serval:BIB_EE544EB386BD
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.
Périodique
Annals of oncology
Auteur⸱e⸱s
Peters S., Reck M., Smit E.F., Mok T., Hellmann M.D.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Statut éditorial
Publié
Date de publication
01/06/2019
Peer-reviewed
Oui
Volume
30
Numéro
6
Pages
884-896
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
Antibodies that target programmed death 1 (PD-1) or its ligand [programmed death ligand 1 (PD-L1)] have become a mainstay of first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC) without targetable genetic alterations. In this review, we summarize results from recent clinical trials that have evaluated the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies atezolizumab and durvalumab as first-line treatment as monotherapy and in combination with chemotherapy, other immunotherapies, and antiangiogenesis agents. We discuss factors that may influence treatment selection, including patient baseline clinical and demographic characteristics, tumor histology, and biomarkers such as PD-L1 expression and tumor mutation burden. While immunotherapy has become a central component of first-line treatment of most patients with advanced NSCLC, important questions remain about how treatment should be managed for individual patients.
Mots-clé
Antineoplastic Agents, Immunological/therapeutic use, B7-H1 Antigen/antagonists & inhibitors, B7-H1 Antigen/immunology, Biomarkers, Tumor/immunology, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/immunology, Carcinoma, Non-Small-Cell Lung/pathology, Humans, Immunotherapy/methods, Lung Neoplasms/drug therapy, Lung Neoplasms/immunology, Lung Neoplasms/pathology, Molecular Targeted Therapy, Patient Selection, Prognosis, NSCLC, combination therapy, first line, immunotherapy, monotherapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
14/04/2019 16:51
Dernière modification de la notice
18/08/2020 6:21
Données d'usage